

Image of Ebola viruses exiting host cells - Courtesy of NIAID

JIM JOYCE - FOUNDER & CEO

BIO INTERNATIONAL CONFERENCE

JUNE 6, 2018

aethlon MEDICAL, INC.

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE

aethlon MEDICAL, INC.

Mission

To Save Lives

Our Lead therapeutic Candidate

A first-in-class therapeutic technology

The Hemopurifier®

A Broad-spectrum Virus Treatment Candidate

Designed for the single-use removal of infectious viruses from blood

aethlon MEDICAL, INC.

DEPLOYED FOR USE ON THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT INSTRUMENTS

THE HEMOPURIFIER®

A BROAD-SPECTRUM VIRUS TREATMENT CANDIDATE

DESIGNED FOR THE SINGLE-USE REMOVAL OF INFECTIOUS VIRUSES FROM BLOOD

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Mechanism of action

- Rapid real-time elimination of circulating viruses
- Glycan Shield Capture Mechanism allows Broad-spectrum virus capture
- Companion assay reinforces mechanism performance

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Market opportunity

- Life-threatening bioterror & Pandemic threat viruses
- Latent viral pathogens in immune compromised Individuals
- Antiviral drug resistant viruses
- Oncology - tumor derived Exosomes

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Clinical Activities

- *In vitro* Capture validations of 16 high-threat viral pathogens
- Four investigational human studies completed outside U.S.
- Conclusion of U.S. feasibility study (March 2017)
- Receives Expedited Access Pathway Designation from FDA (September 2017)

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Designated "Breakthrough Device" by FDA

FDA

THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS DESIGNATED THE AETHLON HEMOPURIFIER® TO THE "BREAKTHROUGH DEVICE" PROGRAM ESTABLISHED THROUGH THE 21ST CENTURY CURES ACT

aethlon MEDICAL, INC.

UNDER THE "BREAKTHROUGH DEVICE" DESIGNATION, THE FDA PERMITTED THE PROPOSED INDICATION FOR USE TO INCLUDE: ***"THE HEMOPURIFIER IS A SINGLE-USE DEVICE INDICATED FOR THE TREATMENT OF LIFE-THREATENING HIGHLY GLYCOSYLATED VIRUSES THAT ARE NOT ADDRESSED WITH AN APPROVED TREATMENT."***

National Institute of Allergy and Infectious Diseases

LIFE-THREATENING VIRUSES IN THE UNITED STATES

- 42 VIRUSES CLASSIFIED AS LIFE-THREADING CATEGORY A, B OR C PATHOGEN THREATS
- 40 ARE GLYCOSYLATED
- 38 ARE NOT ADDRESSED WITH AN APPROVED POST-EXPOSURE THERAPY

aethlon MEDICAL, INC.



Ebola Image Courtesy of NIAID

EBOLA VIRUS

A CASE STUDY IN TREATING A LIFE-THREATENING VIRUS NOT ADDRESSED WITH AN APPROVED THERAPY

aethlon MEDICAL, INC.

Frankfurt University Hospital

EMERGENCY-USE APPROVAL FROM GERMANY'S FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES (BFARM) TO ADMINISTER HEMOPURIFIER® THERAPY TO AN EBOLA-INFECTED PHYSICIAN AT FRANKFURT UNIVERSITY HOSPITAL.

The treatment of Ebola virus

A single 6.5-hour administration of Hemopurifier® therapy was delivered to the patient, who was comatose with multiple organ failure.

aethlon MEDICAL, INC.

Ebola Treatment Results

Presented at the American Society of Nephrology Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Frankfurt University Hospital

- Hemopurifier® therapy was well tolerated with no adverse events
- Pre-treatment viral load prior was measured to be 400,000 copies/ml
- Post-treatment viral load was measured at 1,000 copies/ml
- Patient made a full recovery

The treatment of Ebola virus

Dr. Stefan Büttner holding the Hemopurifier® after treatment

aethlon MEDICAL, INC.

Virus Capture Assay Result

242 million copies of Ebola virus captured within the Hemopurifier® during the 6.5 hour treatment

Analysis: BSL4 Lab
Philipps University Marburg
(O. Dolnik/M. Eickmann/S. Becker)

HEMOPURIFIER®

IN VITRO CAPTURE VALIDATIONS

aethlon MEDICAL, INC.

Hemopurifier® in vitro capture validations

Chronic & Latent Viruses



- ☑ Human Immunodeficiency Virus (Aethlon Research Team & Sigma New Life Hospital)
- ☑ Hepatitis C Virus (Aethlon Research Team & Apollo, Fortis, Medicity and Davita Medical Center)
- ☑ Cytomegalovirus (DOD-DARPA)
- ☑ Epstein-Barr Virus (DOD-DARPA)
- ☑ Herpes Simplex Virus-1 (DOD-DARPA)

Hemopurifier® in vitro capture validations

Mosquito-Borne Viruses

- ☑ Chikungunya (National Institute of Virology)
- ☑ Dengue (National Institute of Virology & DARPA)
- ☑ West Nile (Battelle Memorial Research Institute)
- ☑ Zika (Aethlon Research Team)

Hemopurifier® in vitro capture validations

Pandemic Influenza Viruses

- ☑ H1N1 Swine Flu (Aethlon Research Team)
- ☑ H5N1 Bird Flu (Battelle Memorial Research Institute)
- ☑ Spanish Flu of 1918-R (Battelle MRI)

Actual Spanish Flu of 1918 pandemic resulted in approximately 50 million deaths worldwide.



aethlon MEDICAL, INC.

Hemopurifier® in vitro capture validations

Bioterror & Pandemic Threat Viruses

- ☑ Lassa (Southwest Foundation for Biomedical Research)
- ☑ MERS-CoV (Goethe University Research Institute)
- ☑ Smallpox (Battelle Memorial Research Institute) (based on Monkeypox & Vaccinia models)
- ☑ Ebola (CDC, USAMRIID & Frankfurt University Hospital)

WHAT'S NEXT?

THE AETHLON HEMOPURIFIER®

An FDA Designated "Breakthrough Device"

FDA

GUIDANCE FROM THE FDA ON HOW WE CLINICALLY ADVANCE OUR "BREAKTHROUGH DEVICE" INDICATION FOR USE

aethlon MEDICAL, INC.

TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE

aethlon MEDICAL, INC.

Mission

To Save Lives

9635 Granite Ridge Drive, Suite 100
San Diego, California 92123
858.459.7800
Nasdaq: AEMD
www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com